drugset / Trial / NCT00020735

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00020735

RandomizedParallel-groupOpen-labelPrevention

Summary

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using toremifene may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene followed by radical prostatectomy in treating patients who have stage I or stage II prostate cancer.

Timeline

Start
2001-04
Primary completion
2005-01
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Toremifene Small molecule Oral

Indications